Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics is a biotech firm working on gene-editing technology to potentially cure serious diseases by fixing DNA directly inside the body.
Is Intellia Therapeutics, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Pioneering technology with the potential to treat previously incurable diseases. Worth weighing: No current revenue or profit from product sales.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Intellia Therapeutics, Inc. do?
Intellia is essentially a scientific research powerhouse focused on CRISPR technology, which acts like a pair of molecular scissors to edit faulty genes. Because they are still in the testing phase for their treatments, they aren't yet making a profit from sales, meaning they rely on cash reserves to fund their expensive lab work. Everything hinges on their progress in clinical trials, since future success depends entirely on proving these complex treatments are safe and effective for patients.
On our factor screen it looks strongest on value and quality, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- !Revenue slipped about 46% over the year
- ✓Low debt - a sturdier balance sheet
- —
- Quality screens low
- Growth screens low
- Momentum screens low
- Income screens low
Does Intellia Therapeutics, Inc. pay a dividend?
No - Intellia Therapeutics, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Intellia Therapeutics, Inc. have more cash or more debt?
It holds about $437.76M in cash against about $73.41M of debt - so it has net cash of about $364.35M. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Intellia Therapeutics, Inc.'s numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Intellia Therapeutics, Inc. actually fallen?
Over the last 2 years of daily prices, Intellia Therapeutics, Inc. fell as much as −73% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns Intellia Therapeutics, Inc.?
About 82% of Intellia Therapeutics, Inc., or about 82 in every 100 shares, is held by big institutions such as pension and index funds, and company insiders hold about 4%. The rest, roughly 14%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Intellia Therapeutics, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
When does Intellia Therapeutics, Inc. report earnings, and how did recent quarters go?
Intellia Therapeutics, Inc. is next scheduled to report on about 2026-11-05 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-08-06 | $-0.79 | $-0.80 | Missed -2% |
| 2026-05-11 | $-0.90 | $-0.81 | Beat +10% |
| 2026-02-26 | $-0.96 | $-0.83 | Beat +14% |
| 2025-11-06 | $-0.98 | $-0.92 | Beat +7% |
| 2025-08-07 | $-1.01 | $-0.98 | Beat +3% |
| 2025-05-08 | $-1.27 | $-1.10 | Beat +13% |
Across the last 6 quarters here, Intellia Therapeutics, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Intellia Therapeutics, Inc.?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Commercialisation of a successful gene therapy
Inability to bring a product to market
What are the pros and cons of Intellia Therapeutics, Inc.?
A balance check, not a score or verdict.
- Pioneering technology with the potential to treat previously incurable diseases
- Strong intellectual property portfolio in the CRISPR field
- High interest from the scientific and medical community
- No current revenue or profit from product sales
- High cash burn rate to support research
- Highly volatile share price compared to the broader market
- Clinical trial failures could halt development entirely
- Regulatory hurdles could delay or block product launches
- Need for future funding could lead to diluting existing shareholders
The write-up's own warning lights — if these start happening, the case above changes.
- A permanent halt to all clinical trial activity
- A major breakthrough by a competitor that renders their technology obsolete
Common questions about Intellia Therapeutics, Inc.
Does Intellia Therapeutics, Inc. pay a dividend?
No - Intellia Therapeutics, Inc. does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Intellia Therapeutics, Inc. report earnings next?
Intellia Therapeutics, Inc. is next scheduled to report results on about 2026-11-05. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Novavax, Inc.
Smith & Nephew
Bristol-Myers Squibb Company
Align Technology, Inc.
Craneware plc
Genus plc
PureTech Health plc
Eli LillyBuilt from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.